Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types
A Szarewski - Expert review of vaccines, 2012 - Taylor & Francis
Cervical cancer is the third most common cancer in women worldwide and often affects
women under 40 years of age with young families. Vaccination against HPV is a major …
women under 40 years of age with young families. Vaccination against HPV is a major …
Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer
Cervical cancer continues to be the second largest cause of cancer deaths in women
worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) is a …
worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) is a …
Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix®
TF Schwarz - Advances in therapy, 2009 - Springer
Persistent infection with human papillomavirus (HPV) is a necessary cause of cervical
cancer, resulting annually in 274,000 deaths worldwide. Two prophylactic HPV vaccines are …
cancer, resulting annually in 274,000 deaths worldwide. Two prophylactic HPV vaccines are …
HPV vaccine: Cervarix
A Szarewski - Expert opinion on biological therapy, 2010 - Taylor & Francis
Importance of the field: Cervical cancer is a major cause of morbidity and mortality
worldwide and is common in relatively young women. Cervical screening programs, while …
worldwide and is common in relatively young women. Cervical screening programs, while …
A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and …
D Jenkins - Gynecologic oncology, 2008 - Elsevier
Human papilloma virus (HPV)-16 and-18 are responsible for approximately 70% of invasive
cervical cancers worldwide. Other oncogenic HPV types account for almost all the …
cervical cancers worldwide. Other oncogenic HPV types account for almost all the …
[HTML][HTML] HPV vaccines–a review of the first decade
DM Harper, LR DeMars - Gynecologic oncology, 2017 - Elsevier
Abstract Pre-adolescent girls (9–15 years) have the option of receiving a two dose HPV
vaccine series at either a six month or one year interval to provide protection from HPV 16 …
vaccine series at either a six month or one year interval to provide protection from HPV 16 …
A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil®)
VA Govan - Therapeutics and clinical risk management, 2008 - Taylor & Francis
Human papillomaviruses (HPVs) are one of the most common sexually transmitted
infections and remains a public health problem worldwide. There is strong evidence that …
infections and remains a public health problem worldwide. There is strong evidence that …
AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention
TF Schwarz - Expert review of vaccines, 2008 - Taylor & Francis
Persistent infection with oncogenic human papillomavirus (HPV)-16 and-18 accounts for
over 70% of all cases of cervical cancer. Vaccination against these HPV types has become a …
over 70% of all cases of cervical cancer. Vaccination against these HPV types has become a …
Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®)
K McKeage, B Romanowski - BioDrugs, 2011 - Springer
The AS04-adjuvanted human papillomavirus (HPV) 16/18 vaccine (Cervarix®) is a
noninfectious recombinant vaccine produced using purified virus-like particles (VLPs) that …
noninfectious recombinant vaccine produced using purified virus-like particles (VLPs) that …
Currently approved prophylactic HPV vaccines
DM Harper - Expert review of vaccines, 2009 - Taylor & Francis
Cervarix® and Gardasil® are two prophylactic HPV vaccines designed primarily for cervical
cancer prevention. Cervarix is effective against HPV-16,-18,-31,-33 and-45, the five most …
cancer prevention. Cervarix is effective against HPV-16,-18,-31,-33 and-45, the five most …